IGPA meeting: Costs to be central to biosimilars' success
This article was originally published in SRA
While the lack of clarity in biosimilars legislation in the US may be causing much gnashing of industry teeth1, the lingering uncertainty, in fact, does not really matter that much. That is because the first big losses of exclusivity for blockbuster biologics in this market will not happen for a few years yet.
You may also be interested in...
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.